Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial
Background: Signs of feeding intolerance are common in formula-fed infants. We evaluated the clinical response to a partially hydrolyzed 100% whey protein formula with high sn -2 palmitate and reduced lactose (FA) and to an alpha-lactalbumin-enriched whey-predominant intact protein formula with full...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-09-01
|
Series: | Global Pediatric Health |
Online Access: | https://doi.org/10.1177/2333794X20954332 |
id |
doaj-bc4317ae34c8460881746e0635fe1cf1 |
---|---|
record_format |
Article |
spelling |
doaj-bc4317ae34c8460881746e0635fe1cf12020-11-25T03:14:02ZengSAGE PublishingGlobal Pediatric Health2333-794X2020-09-01710.1177/2333794X20954332Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized TrialBoosba Vivatvakin MD0Elvira Estorninos MD1Reyin Lien MD2Hung Chang Lee MD3Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM4Jowena Lebumfacil PhD5Colin I Cercamondi PhD6Sheri Volger PhD, RDN7Chulalongkorn University, Bangkok, ThailandAsian Hospital and Medical Center, Muntinlupa City, PhilippinesChang Gung Memorial Hospital, Taoyuan, TaiwanMackay Memorial Hospital, Taipei, TaiwanThe Chinese University of Hong Kong, Shatin, N.T., Hong KongWyeth Nutrition, Makati City, Manila, PhilippinesNestlé Product Technology Center – Nutrition, Société des Produits Nestlé S.A., Vevey, SwitzerlandNestlé Product Technology Center – Nutrition, Société des Produits Nestlé S.A., Vevey, SwitzerlandBackground: Signs of feeding intolerance are common in formula-fed infants. We evaluated the clinical response to a partially hydrolyzed 100% whey protein formula with high sn -2 palmitate and reduced lactose (FA) and to an alpha-lactalbumin-enriched whey-predominant intact protein formula with full lactose (FB) in healthy full-term infants with parent-reported signs of feeding intolerance. Methods: In a double-blind, parallel-group trial in 6 Asian study centers, exclusively formula-fed infants aged 30 to 90 days, whose parents reported fussiness-crying for ≥2 hours/day plus gassiness and/or stooling difficulty, and intended to switch formula, were randomly assigned to FA (n = 130) or FB (n = 129) for 14 days. Primary endpoint was daily duration of fussiness-crying. Secondary endpoints included gassiness, spitting-up, vomiting, sleep pattern, Infant Gastrointestinal Symptom Questionnaire (IGSQ) Index, infant temperament and maternal anxiety. Results: Mean ± SE minutes/day of fussiness-crying in the 256 analyzed infants (FA, n = 127 and FB, n = 129) substantially decreased from baseline to study end in FA (291 ± 14 to 140 ± 8; –52%, P < .001), and FB (313 ± 14 to 153 ± 11, –51%, P < .001) with no difference between groups. Similarly, gassiness, spitting-up, vomiting and sleep pattern significantly improved by study end for both formulas. Mean ± SE IGSQ index scores significantly decreased from baseline to study end (FA: 44.5 ± 0.9 to 28.6 ± 0.7; FB: 44.5 ± 0.8 to 29.0 ± 0.7; P < .001) with no differences between groups. Infant temperament and maternal anxiety also improved significantly in both groups by study end. Conclusion: Switching from standard, full-lactose, intact whey/casein infant formulas to either study formula resulted in an improvement of gastrointestinal symptoms and associated behaviors in infants with signs of feeding intolerance. Trial Registration: https://clinicaltrials.gov , NCT02021058https://doi.org/10.1177/2333794X20954332 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Boosba Vivatvakin MD Elvira Estorninos MD Reyin Lien MD Hung Chang Lee MD Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM Jowena Lebumfacil PhD Colin I Cercamondi PhD Sheri Volger PhD, RDN |
spellingShingle |
Boosba Vivatvakin MD Elvira Estorninos MD Reyin Lien MD Hung Chang Lee MD Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM Jowena Lebumfacil PhD Colin I Cercamondi PhD Sheri Volger PhD, RDN Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial Global Pediatric Health |
author_facet |
Boosba Vivatvakin MD Elvira Estorninos MD Reyin Lien MD Hung Chang Lee MD Kam Lun Ellis Hon MBBS, MD, FAAP, FCCM Jowena Lebumfacil PhD Colin I Cercamondi PhD Sheri Volger PhD, RDN |
author_sort |
Boosba Vivatvakin MD |
title |
Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial |
title_short |
Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial |
title_full |
Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial |
title_fullStr |
Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial |
title_full_unstemmed |
Clinical Response to Two Formulas in Infants with Parent-Reported Signs of Formula Intolerance: A Multi-Country, Double-Blind, Randomized Trial |
title_sort |
clinical response to two formulas in infants with parent-reported signs of formula intolerance: a multi-country, double-blind, randomized trial |
publisher |
SAGE Publishing |
series |
Global Pediatric Health |
issn |
2333-794X |
publishDate |
2020-09-01 |
description |
Background: Signs of feeding intolerance are common in formula-fed infants. We evaluated the clinical response to a partially hydrolyzed 100% whey protein formula with high sn -2 palmitate and reduced lactose (FA) and to an alpha-lactalbumin-enriched whey-predominant intact protein formula with full lactose (FB) in healthy full-term infants with parent-reported signs of feeding intolerance. Methods: In a double-blind, parallel-group trial in 6 Asian study centers, exclusively formula-fed infants aged 30 to 90 days, whose parents reported fussiness-crying for ≥2 hours/day plus gassiness and/or stooling difficulty, and intended to switch formula, were randomly assigned to FA (n = 130) or FB (n = 129) for 14 days. Primary endpoint was daily duration of fussiness-crying. Secondary endpoints included gassiness, spitting-up, vomiting, sleep pattern, Infant Gastrointestinal Symptom Questionnaire (IGSQ) Index, infant temperament and maternal anxiety. Results: Mean ± SE minutes/day of fussiness-crying in the 256 analyzed infants (FA, n = 127 and FB, n = 129) substantially decreased from baseline to study end in FA (291 ± 14 to 140 ± 8; –52%, P < .001), and FB (313 ± 14 to 153 ± 11, –51%, P < .001) with no difference between groups. Similarly, gassiness, spitting-up, vomiting and sleep pattern significantly improved by study end for both formulas. Mean ± SE IGSQ index scores significantly decreased from baseline to study end (FA: 44.5 ± 0.9 to 28.6 ± 0.7; FB: 44.5 ± 0.8 to 29.0 ± 0.7; P < .001) with no differences between groups. Infant temperament and maternal anxiety also improved significantly in both groups by study end. Conclusion: Switching from standard, full-lactose, intact whey/casein infant formulas to either study formula resulted in an improvement of gastrointestinal symptoms and associated behaviors in infants with signs of feeding intolerance. Trial Registration: https://clinicaltrials.gov , NCT02021058 |
url |
https://doi.org/10.1177/2333794X20954332 |
work_keys_str_mv |
AT boosbavivatvakinmd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT elviraestorninosmd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT reyinlienmd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT hungchangleemd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT kamlunellishonmbbsmdfaapfccm clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT jowenalebumfacilphd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT colinicercamondiphd clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial AT sherivolgerphdrdn clinicalresponsetotwoformulasininfantswithparentreportedsignsofformulaintoleranceamulticountrydoubleblindrandomizedtrial |
_version_ |
1724644953407094784 |